ITMCTR2000003759
Not yet recruiting
Phase 1
A randomized, double-blind, controlled clinical study on the effectiveness and safety of Gualou Guanxin Heji in the treatment of coronary heart disease angina pectoris (qi deficiency and blood stasis syndrome)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shanghai Municipal Hospital of Traditional Chinese Medicine
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Those who meet the diagnostic criteria for coronary heart disease and angina;
- •2\) Those who meet the diagnostic criteria for stable fatigue\-type angina;
- •3\) Those who meet the grades I and II of fatigued angina;
- •4\) Those who meet the diagnostic criteria of Qi deficiency and blood stasis syndrome in TCM;
- •5\) The electrocardiogram has obvious ischemic changes (ordinary electrocardiogram ST segment level down \>\= 1\.0mm, or/and R wave\-based lead T wave inversion \>\= 2\.0mm);
- •6\) The electrocardiogram has ischemic changes, but does not meet the above\-mentioned standard 5, and the result of exercise electrocardiogram is positive, or it is confirmed by one of the three methods of coronary angiography, radionuclide myocardial scan, and 64\-slice CT Coronary artery stenosis;
- •7\) Those who have had angina pectoris more than 2 times a week;
- •8\) 8 points \<\= angina pectoris starting score \<\= 12 points and TCM syndrome starting score \>\= 8 points;
- •9\) Between the ages of 35 and 65, there is no restriction on men and women;
- •10\) According to GCP regulations, obtain informed consent and take the test voluntarily.
Exclusion Criteria
- •1\) Those who are confirmed to have chest pain caused by coronary heart disease, acute myocardial infarction, other heart diseases, severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, biliary heart disease, gastric and esophageal reflux, etc.;
- •2\) Those who have undergone coronary revascularization within half a year;
- •3\) Combined with severe hypertension (systolic blood pressure \>\= 180mmHg, diastolic blood pressure \>\= 110mmHg), severe cardiopulmonary insufficiency, severe arrhythmia (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.), liver, kidney, hematopoietic system, etc. Primary diseases, mental patients;
- •4\) Pregnant, lactating women or women with pregnancy intentions;
- •5\) People with allergies and allergies to this medicine;
- •6\) Have a history of drug abuse;
- •7\) Those who are participating in other drug clinical trials.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A randomized double-blind controlled study of Shuhe Granules in treating heart and kidney deficiency and Qi and blood disharmony syndrome of chronic insomnia disorderinsomniaITMCTR2023000013Guangdong Provincial hospital of Traditional Chinese Medicine
Recruiting
Phase 1
A randomized, double-blind, controlled clinical study on the intervention of Shudi Suoyang Decoction granule in PF-ILD with kidney essence deficiency syndromeITMCTR2100004924Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University
Recruiting
Phase 1
A randomized, controlled, double-blind clinical study of Jiawei Qilang Decoction in the treatment of drug dependent constipatiodrug dependent constipationITMCTR2000003862Shanghai Municipal Hospital of Traditional Chinese Medicine
Not yet recruiting
Phase 2
A randomized, double-blind, controlled clinical trial of Suhe Granules for chronic insomnia patients with Disharmony of Qi and Blood and Deficiency of Heart and KidneyinsomniaITMCTR2200006603Guangdong Provincial Hospitai of Chinese Medicine
Active, not recruiting
Not Applicable
A clinical trial to assess the Efficacy and safety of liposomal Curcumin in subjects with metabolic syndromeHealth Condition 1: null- Metabolic syndromeCTRI/2017/06/008903CureSupport